PET/CT and renal pathology: A blind spot for radiologists? Part 2 - Lymphoma, leukemia, and metastatic disease

Katherine Zukotynski; Aaron Lewis; Kevin O'Regan; Heather Jacene; Christopher Sakellis; Samuel Almodovar; David Israel

doi:10.2214/AJR.11.7923

PET/CT and renal pathology: A blind spot for radiologists? Part 2 - Lymphoma, leukemia, and metastatic disease

Katherine Zukotynski, Aaron Lewis, Kevin O'Regan, Heather Jacene, Christopher Sakellis, Samuel Almodovar, David Israel

Research output: Contribution to journal › Review article › peer-review

17 Scopus citations

Abstract

OBJECTIVE. PET/CT with ¹⁸F-FDG is a powerful tool to evaluate patients with hematologic malignancy or to assess the burden of metastatic disease from solid tumors. Metabolically active renal pathology associated with lymphoma, leukemia, or metastatic disease can be missed without close attention to both the PET and CT portions of the study because of physiologic FDG excretion in the kidneys. This article illustrates the appearance of tracer uptake and the key anatomic features of lymphoma, leukemia, and metastatic disease involving the kidney on FDG PET/CT. CONCLUSION. Close attention to both the FDG PET and CT portions of an FDG PET/CT study is essential to evaluate the kidneys in oncology patients.

Original language	English (US)
Pages (from-to)	W168-W174
Journal	American Journal of Roentgenology
Volume	199
Issue number	2
DOIs	https://doi.org/10.2214/AJR.11.7923
State	Published - Aug 2012
Externally published	Yes

Keywords

FDG PET/CT
Oncology
Renal pathology

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.2214/AJR.11.7923

Cite this

@article{7cde2dc8803a47e696abc98905813bd0,

title = "PET/CT and renal pathology: A blind spot for radiologists? Part 2 - Lymphoma, leukemia, and metastatic disease",

abstract = "OBJECTIVE. PET/CT with 18F-FDG is a powerful tool to evaluate patients with hematologic malignancy or to assess the burden of metastatic disease from solid tumors. Metabolically active renal pathology associated with lymphoma, leukemia, or metastatic disease can be missed without close attention to both the PET and CT portions of the study because of physiologic FDG excretion in the kidneys. This article illustrates the appearance of tracer uptake and the key anatomic features of lymphoma, leukemia, and metastatic disease involving the kidney on FDG PET/CT. CONCLUSION. Close attention to both the FDG PET and CT portions of an FDG PET/CT study is essential to evaluate the kidneys in oncology patients.",

keywords = "FDG PET/CT, Oncology, Renal pathology",

author = "Katherine Zukotynski and Aaron Lewis and Kevin O'Regan and Heather Jacene and Christopher Sakellis and Samuel Almodovar and David Israel",

year = "2012",

month = aug,

doi = "10.2214/AJR.11.7923",

language = "English (US)",

volume = "199",

pages = "W168--W174",

journal = "American Journal of Roentgenology",

issn = "0361-803X",

publisher = "American Roentgen Ray Society",

number = "2",

}

TY - JOUR

T1 - PET/CT and renal pathology

T2 - A blind spot for radiologists? Part 2 - Lymphoma, leukemia, and metastatic disease

AU - Zukotynski, Katherine

AU - Lewis, Aaron

AU - O'Regan, Kevin

AU - Jacene, Heather

AU - Sakellis, Christopher

AU - Almodovar, Samuel

AU - Israel, David

PY - 2012/8

Y1 - 2012/8

N2 - OBJECTIVE. PET/CT with 18F-FDG is a powerful tool to evaluate patients with hematologic malignancy or to assess the burden of metastatic disease from solid tumors. Metabolically active renal pathology associated with lymphoma, leukemia, or metastatic disease can be missed without close attention to both the PET and CT portions of the study because of physiologic FDG excretion in the kidneys. This article illustrates the appearance of tracer uptake and the key anatomic features of lymphoma, leukemia, and metastatic disease involving the kidney on FDG PET/CT. CONCLUSION. Close attention to both the FDG PET and CT portions of an FDG PET/CT study is essential to evaluate the kidneys in oncology patients.

AB - OBJECTIVE. PET/CT with 18F-FDG is a powerful tool to evaluate patients with hematologic malignancy or to assess the burden of metastatic disease from solid tumors. Metabolically active renal pathology associated with lymphoma, leukemia, or metastatic disease can be missed without close attention to both the PET and CT portions of the study because of physiologic FDG excretion in the kidneys. This article illustrates the appearance of tracer uptake and the key anatomic features of lymphoma, leukemia, and metastatic disease involving the kidney on FDG PET/CT. CONCLUSION. Close attention to both the FDG PET and CT portions of an FDG PET/CT study is essential to evaluate the kidneys in oncology patients.

KW - FDG PET/CT

KW - Oncology

KW - Renal pathology

UR - http://www.scopus.com/inward/record.url?scp=84864750854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864750854&partnerID=8YFLogxK

U2 - 10.2214/AJR.11.7923

DO - 10.2214/AJR.11.7923

M3 - Review article

C2 - 22826418

AN - SCOPUS:84864750854

SN - 0361-803X

VL - 199

SP - W168-W174

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

IS - 2

ER -

PET/CT and renal pathology: A blind spot for radiologists? Part 2 - Lymphoma, leukemia, and metastatic disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this